Literature DB >> 18313431

Dietary supplement use in individuals living with cancer and other chronic conditions: a population-based study.

Melissa Farmer Miller1, Keith M Bellizzi, Meryl Sufian, Anita H Ambs, Michael S Goldstein, Rachel Ballard-Barbash.   

Abstract

OBJECTIVE: Cancer survivors are increasingly turning to complementary and alternative medicine (CAM) to manage short- and long-term treatment sequelae. Population-based data on relative use of dietary supplements among cancer survivors compared to those without a cancer history is lacking. Our objective was to compare supplement use among those with and without cancer and among those with and without other chronic conditions, and to identify correlates of supplement use by cancer status.
DESIGN: Cross-sectional, population-based survey of participants in the 2003 CAM supplement to the 2001 California Health Interview Survey.
SUBJECTS: Participants reporting a cancer diagnosis on the 2001 California Health Interview Survey or newly reported diagnosis on the 2003 survey (n=1,844) plus a random oversampling of racial/ethnic minorities (n=7,343). MEASURES: Self-reported use of a multivitamin and 27 vitamins, minerals, herbs, and other natural products during the preceding 12 months. STATISTICAL ANALYSES: Logistic regression analyses were performed with control for potential confounders.
RESULTS: Adults with cancer or other chronic conditions had higher prevalence of supplement use than those reporting no illness. The independent effect of cancer was associated with vitamin use, whereas living with other chronic conditions was associated with all types of supplement use, except multivitamins. Correlates of supplement use were similar between cancer survivors and cancer-free individuals-being a woman, advancing age, and greater physical activity, fruit and vegetable intake, and other CAM use. Among cancer survivors, non-Hispanic whites had the lowest prevalence of herbal supplement use.
CONCLUSIONS: These results indicate that having a chronic medical condition is the major factor associated with supplement use. A diagnosis of cancer, by itself, does not have an independent effect on supplement use. This suggests that most supplement use among cancer survivors is directed at dealing with or preventing the exacerbation of a comorbid condition. Consumers and health professionals should be aware that there is limited information on the effects of dietary supplements taken concurrently with prescription and other over-the-counter medications.

Entities:  

Mesh:

Year:  2008        PMID: 18313431     DOI: 10.1016/j.jada.2007.12.005

Source DB:  PubMed          Journal:  J Am Diet Assoc        ISSN: 0002-8223


  23 in total

1.  Complementary and alternative medicine use among US adults with common neurological conditions.

Authors:  Rebecca Erwin Wells; Russell S Phillips; Steven C Schachter; Ellen P McCarthy
Journal:  J Neurol       Date:  2010-06-11       Impact factor: 4.849

Review 2.  Polypharmacy in older adults with cancer.

Authors:  Ronald J Maggiore; Cary P Gross; Arti Hurria
Journal:  Oncologist       Date:  2010-04-24

3.  Quality of life-related outcomes from a patient-tailored integrative medicine program: experience of Russian-speaking patients with cancer in Israel.

Authors:  Ilanit Shalom Sharabi; Anna Levin; Elad Schiff; Noah Samuels; Olga Agour; Yehudith Tapiro; Efraim Lev; Lital Keinan-Boker; Eran Ben-Arye
Journal:  Support Care Cancer       Date:  2016-05-11       Impact factor: 3.603

4.  Prolonged biologically active colonic tissue levels of curcumin achieved after oral administration--a clinical pilot study including assessment of patient acceptability.

Authors:  Glen R B Irving; Lynne M Howells; Stewart Sale; Ines Kralj-Hans; Wendy S Atkin; Susan K Clark; Robert G Britton; Donald J L Jones; Edwina N Scott; David P Berry; David Hemingway; Andrew S Miller; Karen Brown; Andreas J Gescher; William P Steward
Journal:  Cancer Prev Res (Phila)       Date:  2012-12-11

5.  Complementary and alternative medicine use among US cancer survivors.

Authors:  Gabriella M John; Dawn L Hershman; Laura Falci; Zaixing Shi; Wei-Yann Tsai; Heather Greenlee
Journal:  J Cancer Surviv       Date:  2016-02-26       Impact factor: 4.442

6.  Dietary supplement use among participants of a databank and biorepository at a comprehensive cancer centre.

Authors:  LeQuyen Luc; Charlotte Baumgart; Edward Weiss; Lesley Georger; Christine B Ambrosone; Gary Zirpoli; Susan E McCann
Journal:  Public Health Nutr       Date:  2014-05-27       Impact factor: 4.022

7.  Comparing Reported Dietary Supplement Intakes between Two 24-Hour Recall Methods: The Automated Self-Administered 24-Hour Dietary Assessment Tool and the Interview-Administered Automated Multiple Pass Method.

Authors:  TusaRebecca E Pannucci; Frances E Thompson; Regan L Bailey; Kevin W Dodd; Nancy Potischman; Sharon I Kirkpatrick; Gwen L Alexander; Laura A Coleman; Lawrence H Kushi; Michelle Groesbeck; Maria Sundaram; Heather Clancy; Stephanie M George; Lisa Kahle; Amy F Subar
Journal:  J Acad Nutr Diet       Date:  2018-06       Impact factor: 4.910

8.  Potential medication problems in older newly diagnosed cancer patients in Canada during cancer treatment: a prospective pilot cohort study.

Authors:  Martine T E Puts; Johanne Monette; Veronique Girre; Beatriz Costa-Lima; Christina Wolfson; Gerald Batist; Howard Bergman
Journal:  Drugs Aging       Date:  2010-07-01       Impact factor: 3.923

9.  A randomized, placebo-controlled trial of diindolylmethane for breast cancer biomarker modulation in patients taking tamoxifen.

Authors:  Cynthia A Thomson; H H Sherry Chow; Betsy C Wertheim; Denise J Roe; Alison Stopeck; Gertraud Maskarinec; Maria Altbach; Pavani Chalasani; Chuan Huang; Meghan B Strom; Jean-Philippe Galons; Patricia A Thompson
Journal:  Breast Cancer Res Treat       Date:  2017-05-30       Impact factor: 4.872

10.  Evaluation and implications of natural product use in preoperative patients: a retrospective review.

Authors:  Allison R King; Flint S Russett; Joyce A Generali; Dennis W Grauer
Journal:  BMC Complement Altern Med       Date:  2009-10-13       Impact factor: 3.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.